Tumor cells (direct oncolysis) plus IFN-β and CD40L transgene payloads

Class

Conditionally replicative oncolytic adenovirus encoding immunostimulatory transgenes (interferon-beta and a chimeric CD40-ligand, "MEM40")

Pathway

selectively replicates in and lyses tumor cells while locally expressing IFN-β and CD40L to activate anti-tumor immunity within the tumor microenvironment; given by intratumoral injection, combined with nivolumab or docetaxel

This mechanism combines two complementary anti-cancer strategies within a single agent: a conditionally replicative oncolytic adenovirus and two immunostimulatory transgenes. The virus is engineered so that it replicates preferentially within tumor cells, whose disrupted growth-control pathways allow viral replication to proceed unchecked, while normal cells with intact defenses restrict it. Replication culminates in tumor cell lysis, releasing tumor antigens and immune-alerting molecules. Embedded within the viral genome are genes encoding interferon-beta, a natural antiviral and immune-activating protein, and a CD40-ligand construct, a molecule that engages and licenses antigen-presenting cells to mobilize T-cell responses. Because these genes are expressed locally by the replicating virus rather than delivered systemically, they concentrate immune activation within the tumor microenvironment, aiming to convert tumors that are poorly infiltrated by immune cells into ones that are actively recognized and attacked. This approach is relevant across solid tumor types where checkpoint inhibitor therapies alone are insufficient because too few immune cells are present in the tumor to be reactivated, and where combining local immune priming with systemic checkpoint blockade or chemotherapy may extend anti-tumor activity beyond the injected lesion.